These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 9001568)
1. Carbohydrate antigens as targets for active specific immunotherapy. Ragupathi G Cancer Immunol Immunother; 1996 Nov; 43(3):152-7. PubMed ID: 9001568 [TBL] [Abstract][Full Text] [Related]
2. Augmenting the immunogenicity of carbohydrate tumor antigens. Livingston PO Semin Cancer Biol; 1995 Dec; 6(6):357-66. PubMed ID: 8938274 [TBL] [Abstract][Full Text] [Related]
3. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Ragupathi G; Meyers M; Adluri S; Howard L; Musselli C; Livingston PO Int J Cancer; 2000 Mar; 85(5):659-66. PubMed ID: 10699946 [TBL] [Abstract][Full Text] [Related]
4. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. Slovin SF; Ragupathi G; Musselli C; Fernandez C; Diani M; Verbel D; Danishefsky S; Livingston P; Scher HI Cancer Immunol Immunother; 2005 Jul; 54(7):694-702. PubMed ID: 15726361 [TBL] [Abstract][Full Text] [Related]
5. Carbohydrate vaccines as immunotherapy for cancer. Slovin SF; Keding SJ; Ragupathi G Immunol Cell Biol; 2005 Aug; 83(4):418-28. PubMed ID: 16033538 [TBL] [Abstract][Full Text] [Related]
6. Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience. Musselli C; Livingston PO; Ragupathi G J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R20-6. PubMed ID: 11768620 [TBL] [Abstract][Full Text] [Related]
7. [Gangliosides as carbohydrate antigens associated with cancer and their possible use in tumor immunotherapy]. Horwacik I Przegl Lek; 2004; 61 Suppl 2():14-9. PubMed ID: 15686040 [TBL] [Abstract][Full Text] [Related]
8. Ganglioside vaccines with emphasis on GM2. Livingston P Semin Oncol; 1998 Dec; 25(6):636-45. PubMed ID: 9865678 [TBL] [Abstract][Full Text] [Related]
9. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers. Ragupathi G; Koide F; Sathyan N; Kagan E; Spassova M; Bornmann W; Gregor P; Reis CA; Clausen H; Danishefsky SJ; Livingston PO Cancer Immunol Immunother; 2003 Oct; 52(10):608-16. PubMed ID: 12811527 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines. Kim SK; Ragupathi G; Musselli C; Choi SJ; Park YS; Livingston PO Vaccine; 1999 Nov; 18(7-8):597-603. PubMed ID: 10547417 [TBL] [Abstract][Full Text] [Related]
11. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Ragupathi G; Livingston PO; Hood C; Gathuru J; Krown SE; Chapman PB; Wolchok JD; Williams LJ; Oldfield RC; Hwu WJ Clin Cancer Res; 2003 Nov; 9(14):5214-20. PubMed ID: 14614001 [TBL] [Abstract][Full Text] [Related]
12. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Livingston PO Immunol Rev; 1995 Jun; 145():147-66. PubMed ID: 7590824 [TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of melanoma-associated gangliosides in cancer patients. Tai T; Cahan LD; Tsuchida T; Saxton RE; Irie RF; Morton DL Int J Cancer; 1985 May; 35(5):607-12. PubMed ID: 3997282 [TBL] [Abstract][Full Text] [Related]
14. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines. Ragupathi G; Cappello S; Yi SS; Canter D; Spassova M; Bornmann WG; Danishefsky SJ; Livingston PO Vaccine; 2002 Jan; 20(7-8):1030-8. PubMed ID: 11803062 [TBL] [Abstract][Full Text] [Related]
15. The use of carbohydrate antigens for the preparation of vaccines for therapy in breast cancer. Croce MV; Segal-Eiras A Drugs Today (Barc); 2002 Nov; 38(11):759-68. PubMed ID: 12582459 [TBL] [Abstract][Full Text] [Related]
16. On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines. Ragupathi G; Coltart DM; Williams LJ; Koide F; Kagan E; Allen J; Harris C; Glunz PW; Livingston PO; Danishefsky SJ Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13699-704. PubMed ID: 12359877 [TBL] [Abstract][Full Text] [Related]
17. Recent advances in developing synthetic carbohydrate-based vaccines for cancer immunotherapies. Hevey R; Ling CC Future Med Chem; 2012 Mar; 4(4):545-84. PubMed ID: 22416779 [TBL] [Abstract][Full Text] [Related]
18. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Hakomori S Adv Exp Med Biol; 2001; 491():369-402. PubMed ID: 14533809 [TBL] [Abstract][Full Text] [Related]
19. A cancer vaccine based on fluorine-modified sialyl-Tn induces robust immune responses in a murine model. Song C; Zheng XJ; Liu CC; Zhou Y; Ye XS Oncotarget; 2017 Jul; 8(29):47330-47343. PubMed ID: 28537884 [TBL] [Abstract][Full Text] [Related]